Skip to main content

David Martinez Selva

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

David Martinez Selva

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

DESARROLLO DE EDL6D, UN PÉPTIDO MIMÉTICO DE SHBG PARA EL TRATAMIENTO DE LA ENFERMEDAD DEL HÍGADO GRASO NO ALCOHÓLICO (NAFLD) Y LA ESTEATOHEPATITIS NO ALCOHÓLICA (NASH)

IP: David Martinez Selva
Collaborators: Lidia Fuertes Rioja
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 370568
Reference: CPP2022-009831
Duration: 01/07/2023 - 30/06/2026

Ministerio de Ciencia

Funciones Alternativas de la Sex Hormone-Binding Globulin: Mecanismos Moleculares y Papel en Fisiología y Fisiopatología

IP: David Martinez Selva
Collaborators: Maria Teresa Salcedo Allende, Lorena Ramos Pérez, Pablo Gabriel Medina, Pilar Costa Forner
Funding agency: Instituto de Salud Carlos III
Funding: 190000
Reference: PI23/00544
Duration: 01/01/2024 - 31/12/2026

New Biomarker for NAFLD and NASH Development and Progression

IP: David Martinez Selva
Collaborators: -
Funding agency: Fundació "La Caixa"
Funding: 50000
Reference: CAIXAIMPULSE/CI23-20154
Duration: 12/12/2023 - 12/12/2025

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Judit Amigó Farran, Mercè Abad Martín, Marta Comas Martínez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Núria García Doladé

Núria García Doladé

Predoctoral researcher
Clinical Pharmacology
Read more
Jordi Sabadell García

Jordi Sabadell García

General Surgery
Read more
Maria Sellés Altés

Maria Sellés Altés

Research technician
Neurodegenerative Diseases
Read more
M. Helena  Closa Castells

M. Helena Closa Castells

Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.